We read the hundred-plus public sources you don't have time to read, then hand you what moved, what it means for your position, and what to do first.
Not a deck, a decision.
If one of these is the position you are in, that is exactly what this report is built for.
The board has not committed. You believe the market is real but you need the map, the structure and the risks named before they will approve it.
You are convinced the opportunity exists. You need evidence the board cannot dispute, sourced and defensible, not a market-size slide from an analyst firm with no skin in the game.
You have been hired into a UK or international commercial role. NICE, the NHS procurement route and the UKCA position are all new to you, and the clock is running.
FDA cleared and selling at home through commercial payers. The UK is the logical next step, but the system is structurally different: a single national payer, value assessment before access, and a different regulatory path. You need the map before the move.
The clinical story is ready. The UK regulatory route, whether UKCA or the new international recognition pathway, is the next gate. You need a clear picture of the regulatory and commercial architecture before you commit the budget.
Direct build, distributor, or an NHS framework and diffusion partner. You know the question. You need to see who has answered it, what each choice cost them, and where each one broke down.
A previous UK attempt did not scale the way the plan said it would. You need to understand where the system defeated you before going back into it.
A UK-native or European competitor is already on an NHS framework. You need to find where their position is solid and where it is not, before they find where yours is.
You signed a UK distribution or clinical-operations agreement. Now you need to understand the market your partner is selling into, in enough depth to hold them accountable.
This report serves as a strategic compass, transforming a complex landscape into a clear, prioritised execution plan. It moves the commercial function from a reactive footing to a proactive one: identifying where you can influence specifications before they become live tenders.
One of the most comprehensive and precise analyses I have encountered. Its greatest strength lies in the clarity and practicality of its recommendations. The emphasis on well-defined, executable actions materially enhances its value, enabling a direct transition from analysis to implementation.
The May 2026 UK Home Oxygen report landed on a Commercial Director's desk on a Tuesday. By Thursday he had three actions he had not known to look for: a trust with a procurement window his competitors had not spotted, a competitor field force restructure, and a clinical development that changed how he positioned his next tender submission. He did not search for any of it.
That is the product.
The large intelligence platforms write for markets. This report is written for you, at your company, for the decision in front of you.
The big analyst houses write for sectors and categories. If you want one of them to write for your specific commercial position, the figure runs to tens of thousands and the process runs to months.
The intelligence in this report is not secret. It sits in public sources: procurement portals, regulatory filings, Companies House accounts, clinical trial registers, NHS board papers. The problem is not access. It is time.
Senior commercial leaders in medical devices are not short of expertise. They are short of the hours it takes to read an MHRA safety notice, a competitor's earnings call, and an ICB commissioning consultation that signals a tender consolidation fourteen months out. By the time those signals reach you through normal channels, the window to act on them has usually closed.
We read those sources for you. Every hour of research spent on your market, not somebody's category. Every claim verified against a named source, or declared absent. No estimates without disclosure. No padding.
And because it comes from outside your organisation, it has not been through the filter. Nobody on your team decided what you should and should not see.
Three sections appear in every report. The rest are selected against the question you ask.
Tell us your therapy area, your geography, and the commercial questions that matter most right now. A few minutes, not a procurement process.
The sections your question needs, sourced and verified, with the Action Intelligence, the what-to-do-first section, written for your position, not the category in general.
A designed report you can read on any device. It opens with the Action Intelligence: what to do first, ranked by urgency.
This report does not replace your market knowledge. It covers the ground you do not have time to cover yourself, and tells you what it means before someone else acts on it first.
Scoped to one market: one therapy area, one geography.
The analyst-house version of this costs tens of thousands and takes months. This costs £6,500 and takes five days.
A full report, open access, nothing gated. Same format and the same source discipline as a commissioned report. The Action Intelligence in this one is written for the therapy area generally. In a commissioned report it is written around your commercial position: your brief, your territory, and the competitive questions you have told us matter most.
A 200,000-patient diagnostic backlog forcing the NHS pathway from lab to home, a £160M framework being re-specified, ResMed's leadership transition, and three RED-rated priorities for the leader who moves first.
See the worked example ↗Worked examples in other therapy areas available on request.
Five minutes to brief us. We reply within two working days confirming scope and the questions the report will answer.
Start your brief ↗